Dormant malaria parsites in red blood cells may contribute to treatment failure

Researchers at the University of South Florida (USF) College of Public College Health have shown for the first time in a rodent model that the earliest form of malaria parasites can lay dormant in red blood cells and "wake up," or recover, following treatment with the antimalarial drug artesunate.

The study, which appears Oct. 24, 2011 in the online journal , suggests that this early-stage dormancy phenomenon contributes to the failure of artesunate alone, or even combined with other drugs, to eliminate the mosquito-borne disease. Alexis LaCrue, PhD, research associate in the USF Department of Global Health, is the lead author of the study, which was funded by the National Institute of Allergy and Infectious Diseases (NIAID).

The emergence of parasites resistant to artesunate therapy along the Thai-Cambodian border could seriously undermine the success of global malaria control efforts, the World Health Organization has reported.

"There is an urgent public health need to understand why this resistance is happening and the basis for it, so we can help arrest its spread," said principal investigator Dennis Kyle, PhD, distinguished university health professor at the USF College of Public Health.

"Our study was able to induce the same dormant stage in vivo -- in a rodent malaria model -- that was previously seen only in the test tube," Kyle said. "The work suggests that dormancy is involved in the earliest stage of parasite development in the . It may be a new mechanism for how the parasite avoids being wiped out by artemisinin drugs."

When mice infected with rodent malaria parasites were treated with artesunate, dormant parasites were present in their red 24 hours following treatment. The researchers also found a positive association between the number of dormant parasites present and when re-emerged in the mice.

More studies are needed to help explain the mechanism behind the early-stage dormancy and its contribution to treatment failure.

"Now that we have a robust animal model for studying how the parasites become dormant and then recover," Kyle said, "we may be able to change our dosing regimens and investigate drug partners for artemisinin that are better at killing the dormant parasites."

Malaria parasites are transmitted by the bite of an infected mosquito. In humans, they enter red blood cells and start replicating after being released from the disease's first target, the liver. Once parasites escape into the bloodstream, disease symptoms emerge including chills, fever, headache, body aches, vomiting and exhaustion.

Malaria affects 10 percent of the world's population, killing nearly one million people a year in developing countries and crippling their economies. Most who die or become ill are poor pregnant women and children under age 5 in tropical and subtropical regions of Africa, Asia and South America.

Provided by University of South Florida

not rated yet

Related Stories

Rectal artemisinins rapidly eliminate malarial parasites

Mar 28, 2008

Artemisinin-based suppositories can help ‘buy time’ for malaria patients who face a delay in accessing effective, injectable antimalarials, according to research published in the online open access journal BMC Infectious Di ...

Recommended for you

Sweat-eating bacteria may improve skin health

13 hours ago

Bacteria that metabolize ammonia, a major component of sweat, may improve skin health and some day could be used for the treatment of skin disorders, such as acne or chronic wounds. In a study conducted by AOBiome LLC, human ...

Scientists shed light on cause of spastic paraplegia

15 hours ago

Scientists at The Scripps Research Institute (TSRI) have discovered that a gene mutation linked to hereditary spastic paraplegia, a disabling neurological disorder, interferes with the normal breakdown of triglyceride fat ...

User comments